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Abstract
Introduction:Malignant hyperthermia (MH) and exertional rhabdomyolysis (ERM) have long been considered episodic phenotypes
occurring in response to external triggers in otherwise healthy individuals with variants in RYR1. However, recent studies have
demonstrated a clinical and histopathological continuum between patients with RYR1-related congenital myopathies and those with
ERM or MH susceptibility. Furthermore, animal studies have shown non-neuromuscular features such as a mild bleeding disorder
and an immunological gain-of-function associated with MH/ERM related RYR1 variants raising important questions for further
research. Awareness of the neuromuscular disease spectrum and potential multisystem involvement inRYR1-related MH and ERM is
essential to optimize the diagnostic work-up, improve counselling and and future treatment strategies for patients affected by these
conditions. This study will examine in detail the nature and severity of continuous disease manifestations and their effect on daily life in
patients with RYR1-related MH and ERM.
Methods: The study protocol consists of four parts; an online questionnaire study, a clinical observational study,muscle imaging, and
specific immunological studies.PatientswithRYR1-relatedMHsusceptibility andERMwill be included. The imaging, immunological and
clinical studies will have a cross-sectional design, while the questionnaire study will be performed three times during a year to assess
disease impact, daily living activities, fatigue and pain. The imaging study consists of muscle ultrasound and whole-body magnetic
resonance imaging studies. For the immunological studies, peripheralmononuclear bloodcellswill be isolated for in vitro stimulationwith
toll-like receptor ligands, to examine the role of the immune system in the pathophysiology of RYR1-related MH and ERM.
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Discussion: This study will increase knowledge of the full spectrum of neuromuscular and multisystem features of RYR1-related
MH and ERM and will establish a well-characterized baseline cohort for future studies on RYR1-related disorders. The results of this
study are expected to improve recognition of RYR1-related symptoms, counselling and a more personalized approach to patients
affected by these conditions. Furthermore, results will create new insights in the role of the immune system in the pathophysiology of
MH and ERM.
Trial registration: This study was pre-registered at ClinicalTrials.gov (ID: NCT04610619).
Abbreviations: 4-CmC = 4-Chloro-m-Cresol, CK = Creatine kinase, ERM = Exertional rhabdomyolysis, MH = Malignant
hyperthermia, MHS = Malignant hyperthermia susceptible, MRC = Medical research council, MRI = Magnetic resonance imaging,
PBMC= Peripheral mononuclear blood cells,RYR1=Gene encoding the ryanodine receptor-1, RyR1=Ryanodine receptor-1, STIR
= Short-TI Inversion Recovery, TLR = Toll-like receptor, VIBE = Volumetric interpolated breath-hold examination.
Keywords: calcium signaling, malignant hyperthermia, myopathy, neuromuscular disorder, rhabdomyolysis, Ryanodine receptor-
1, RYR1, skeletal muscle cell
1. Introduction
Variants in RYR1, the gene encoding for the ryanodine receptor-
1 (RyR1), may lead to disturbances of calcium homeostasis in
skeletal muscle and give rise to a wide variety of congenital
myopathies including central core disease, multi-minicore
disease, centronuclear myopathy and congenital fibre type
disproportion.[1,2] Moreover, RYR1 variants account for a
substantial proportion of patients presenting with episodic
conditions as exertional rhabdomyolysis (ERM) and malignant
hyperthermia (MH), a disorder that clinically manifests as a
hypermetabolic crisis after exposure to volatile anesthetics and/or
succinylcholine.[3,4] These episodic phenotypes and RYR1-
related myopathies have long been considered separate entities,
however, recent studies have demonstrated a substantial clinical
and histopathological overlap in patients with congenital
myopathies and ERM or MH susceptibility.[2,5–7]
Although many studies on RYR1-related phenotypes have
focused on the neuromuscular features, recent studies suggest
multisystem involvement in RYR1-related diseases. A study in a
knock-in mouse model with the MH-related RYR1 variant
Y522S showed that this variant leads to prolonged bleeding by
altering vascular smooth muscle cell function.[8] Another study in
the same mouse model showed that this gain-of-function RYR1
variant may offer selective immune advantages due to a more
efficient specific immune response.[9] A role of RYR1 in the
immune system is also supported by the identification of
functional RyR1s in human B-cells and dendritic cells.[10–12]
Furthermore, Epstein-Barr virus-immortalized B-cells from
malignant hyperthermia susceptible (MHS) individuals carrying
the V2168MRYR1 variant are more sensitive to the RyR1 to the
RyR1 activator 4-Chloro-m-Cresol (4-CmC), and produced
more interleukin (IL)-1b and IL-6 after treatment with 4-CmC
and caffeine.[13] This finding provides a potential explanation for
the observation that ERM events often occur during or shortly
after infections.[14] Overall, these findings suggest multisystem
disease manifestations associated with RyR1 dysfunction and
raise important questions for further research. Therefore, a
detailed study is needed to improve the knowledge of the
neuromuscular and multisystem involvement of RYR1-related
diseases, in patients with MH and ERM. This will enable health
care professionals to recognize the whole spectrum of RYR1-
related disease, thus improving the diagnostic work-up and
counselling of patients with RYR1 variants. Furthermore, better
understanding of potentially associated immunological alter-
ations in patients with RYR1 variants will provide more insights
in the immune system as a modifying factor in the pathophysiol-
ogy of ERM and MH.
2. Methods
2.1. Study design
This study is a prospective, cross-sectional cohort study, and will
be performed from August 2020 to August 2023 at the Radboud
University Medical Centre and the Canisius Wilhelmina Hospi-
tal, Nijmegen, The Netherlands. The study protocol was
approved by the regional medical ethics committee (CMO
Arnhem–Nijmegen, registration number 2020-6251) and is pre-
registered at ClinicalTrials.gov (ID: NCT04610619).
2.2. Objective
The primary objective of this study is:
1. To investigate the full spectrum of disease manifestations of
RYR1-related MH/ERM to optimize recognition, acknowl-
edgement and counselling of RYR1-related complaints.
The secondary objectives are:
1. To establish a well-characterized baseline cohort for future
studies on RYR1-related disorders;
2. To investigate the role of the immune system as a potentially
modifying factor in ERM and MH.
2.3. Participants
Subjectswill be recruitedby the treatingphysicians from theMHand
ERM cohorts at the national MH Investigation Unit in the Canisius
Wilhelmina Hospital, Nijmegen and the neuromuscular outpatient
clinic of the Radboud University Medical Centre, Nijmegen.
2.3.1. Inclusion criteria.
1. A history of MH susceptibility or ERM. MH susceptibility is
defined as a pathogenic RYR1 variant (www.emhg.org/
diagnostic-mutations) or a positive in vitro contracture test
(IVCT) according to the European Malignant Hyperthermia
Group diagnostic guideline.[15] A history of ERM is defined as
at least one episode of clinical symptoms of rhabdomyolysis
(cramps, myalgia, myoglobinuria, muscle weakness and/or
muscle swelling) with a sudden increase (> 10.000U/L) and a
subsequent fall of creatine kinase (CK).[16]
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2. Genetically confirmed RYR1 variant classified as pathogenic,
likely pathogenic or a variant of unknown significance
according to the variant curation expert panel recommenda-
tions for RYR1 pathogenicity classifications in MH suscepti-
bility.[17]
3. Speak, read, write and understand Dutch fluently;
4. Age ≥ 18years old.
2.3.2. Exclusion criteria. Patients with the following character-
istics were excluded from participation in this study:
1. Patients with an initial presentation of a RYR1-related
congenital myopathy, manifesting with muscle weakness;
2. Other (neuromuscular) diseases resulting in muscle weakness;
3. Patients with a contra-indication for magnetic resonance
imaging (MRI);
4. Symptoms of angina pectoris;
5. Current malignancy;
6. Patient using systemic steroids for a period > 14days during
the last 3months;
7. Pregnancy or breast-feeding.
2.3.3. Additional exclusion criteria for the immunological
studies.
1. Diabetes mellitus;
2. Established diagnosis of immune deficiency;
3. Fever, surgery or trauma in the last 3months;
4. The use of statins in the last 12months;
5. Patient using systemic steroids for a period over 14 days
during the last 12months.
2.4. Study procedures
This study consists of four main parts, a questionnaire, clinical,
imaging, and immunological part. A total of 20 patients will
participate in all study parts while an additional 20 subjects will
only participate in the questionnaire, clinical and imaging studies.
Furthermore, the questionnaire study is open to all patients
meeting the inclusion criteria, without participation in the other
study parts. The study design is summarized in Figure 1.
2.4.1. Part 1: Questionnaire studies. Validated questionnaires
will be used to asses disease impact including physical activity
(International Physical Activity Questionnaire (IPAQ)),[18,19]
functional impairment (Sickness Impact Profile (SIP)),[20,21] pain
(McGill’s Pain Questionnaire (MPQ)),[22,23] perceived fatigue
(Checklist Individual Strength (CIS)),[24,25] quality of life
(RAND-36),[26,27] mental health (Hospital Anxiety and Depres-
sion Scale (HADS)),[28,29] lower urinary tract symptoms
(International Prostate Symptom Score (IPSS)),[30,31] increased
bleeding tendency (Molecular and Clinical Markers for the
Diagnosis and Management of Type 1 von Willebrand disease
(MCMDM-1VWD Bleeding Questionnaire)),[32] and worries
about the occurrence of aMH or ERM episode (modified version
of the Cancer Worry Scale (CWS)).[33] Furthermore, purpose-
designed questionnaires focusing on neuromuscular, cardiac and
respiratory symptoms will be used as tools to explore topics of
interest for future research.
Subjects included in this part of the study will fill out digital
questionnaires at three-time points; upon recruitment (t=0), at 6
months (t=1) and at 12months (t=2). A detailed timeline of the
study design of the questionnaire study is given in Table 1.
2.4.2. Part 2: Clinical studies. General information on the
medical history, current medication, body weight and height and
results from previous investigations (e.g. muscle biopsies,
electromyography) will be collected from the electronic health
records.
The degree and extent of muscle weakness will be measured
using Medical Research Council (MRC)-scores and quantitative
myometry using a fixed myometry testing. Hypermobility will be
rated using the Bulbena[34] and Beighton score.[35] Respiratory
muscle weakness will be tested using spirometry in sitting and
supine position (vital capacity, forced vital capacity, forced
expiratory volume in the first second). In addition, a timed up and
go test,[36] 30 seconds sit to stand test[37] and a six-minute
walking test will be performed.[38] Furthermore, resting CK levels
will be measured during the visit at the outpatient clinic.
2.4.3. Part 3: Imaging studies. The imaging study consists of
two parts, a muscle ultrasound and a muscle MRI. Previous
studies in facioscapulohumeral dystrophy have shown that these
techniques are complementary, since ultrasound is most sensitive
in early stage of the disease whileMRI sensitivity increases in later
disease stages.[39]
2.4.3.1. Ultrasound. A quantitative and qualitative muscle
ultrasound examination will be performed using an Esaote
MylabTwice ultrasound scanner (Esaote SpA, Genoa, Italy) with
a 3–13MHz broadband linear transducer. The protocol will
include a bilateral ultrasound of the musculus trapezius,
deltoideus, biceps brachii, thoracic and lumbar erector spinae,
iliopsoas, proximal vastus lateralis, biceps femoris and gastroc-
nemius (medial head). The ultrasound protocol was previously
reported elsewhere.[40] Briefly, a strict preset for system settings
will be used to ensure reproducibility. Three consecutive
measurements will be performed, and results will be averaged
offline. For every muscle, a region of interest is drawn manually
to calculate the mean echogenicity using the histogram function
of a custom image analysis package. Using age, sex and weight
corrected reference values, Z-scores (the number of standard
deviations from the mean) will be calculated for each muscle. Z-
scores below 2 (i.e. below the population 95th percentile) are
considered normal.
A semi-quantitative assessment of the images will be performed
using the Heckmatt rating scale which ranges from one (normal
echo-intensity) to four (severely increased echo-intensity with
absent bone reflection) by an experienced neuromuscular ultra-
sonographer.[41]
2.4.3.2. MRI. A whole-body MRI will be performed using a 1,5
Tesla MR system (Avanto Fit, Siemens, Erlangen, Germany).
Volumetric Interpolated Breath-hold Examination (VIBE) 2-
point DIXON (proton density weighted) and Short-TI Inversion
Recovery (STIR) sequences will be acquired. STIR images will be
used as an indicator for edema and/or inflammation. The VIBE 2-
point DIXON images will be used to evaluate muscle volume and
presence of fatty infiltration.
2.4.4. Part 4: Immunology. Immunological investigations will
include a set of laboratory studies using blood samples from a
subset of 20 RYR1 patients and 40 age and sex matched healthy
controls. Healthy controls will be recruited amongst volunteers
from the staff members of the Radboud University Medical
Centre and the Canisius Wilhelmina Hospital.
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Peripheral mononuclear blood cells (PBMC) will be isolated
from EDTA blood of RYR1 patients and healthy controls.
PBMCs will be stimulated for 24hours with the Toll-like receptor
(TLR) ligands Escherichia coli lipopolysaccharide (LPS) and
heat-killed Candida in the presence of RyR1 agonists 4-CmC and
caffeine and/or the RyR1 antagonist dantrolene. Cytokine levels
(IL-1b, IL-6 and TNF-a) in the supernatant of the ERM/MHS
subjects will be compared to healthy controls.[9,12,13] Addition-
ally, circulating cytokines (IL-1b, IL-6) will be measured in all
participating patients.[9]
Paents meeng the inclusion 
criteria are approached to 
parcipate
Family member already 
included in study? 
Excluded
No
Yes
First part of quesonnaire study
(Number of subjects unlimited)
Second part of the quesonnaire study
Informed consent?
Fulfil first part of quesonnaire 
study (n=40)
Yes
Neurological examinaon, 
funconal assessment, imaging 
studies (n=40)
Subject does not parcipate in 
immunological study
No
Immunological studies 
(n=20)
Subject does not 
parcipate in 
immunological studies 
(n=20)
Third part of the quesonnaire study
Time point 1
Inclusion 
Time point 2
6 months 
Time point 3
12 months 
Figure 1. A summary of the study design.
Table 1
Summary of the study design of the questionnaire study.
Questionnaire Time point 1
(inclusion)
Time point 2
(6 months)
Time point 3
(12 months)
IPAQ [18,19] x X x
SIP [20,21] x X x
MPQ [22,23] x X x
CIS [24,25] x X x
RAND-36 [26,27] x X x
HADS [28,29] x x x
IPSS [30,31] x
MCMDM-1VWD Bleeding Questionnaire [32] x
Modified CWS [33] x x x
Neuromuscular symptoms questionnaire x
Cardiovascular symptoms questionnaire x
Respiratory symptoms questionnaire x
IPAQ = International Physical Activity Questionnaire, SIP = Sickness Impact Profile, MPQ = McGill’s Pain Questionnaire, CIS = Checklist Individual Strength, HADS = Hospital Anxiety and Depression Scale IPSS
= International Prostate Symptom Score, MCMDM-1 VWD = Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease, CWS = Cancer Worry Scale.
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2.5. Statistical analysis
Continuous variables will be summarized by their mean and
standard deviation or median and interquartile ranges depending
on its distribution. Categorical data, including ordinal data, will
be summarized in terms of percentages. Results from the
questionnaire studies and cytokine production from RYR1
patients will be compared to normal values and (if applicable)
healthy controls using the students t-test.
Due to the explorative nature of this study we did not perform
a power calculation. For the clinical and imaging studies, 40
subjects will be included since previous studies and case series
with similar sample size showed a substantial clinical and
histopathological overlap in patients with congenital myopathies
and ERM or MH susceptibility.[3,5,6] For the immunological
studies, 20MHS/ERM patients and 40 healthy controls will be
included as previous studies in animal models showed an
immunological gain-of-function in MHS mice in a lower number
of subjects.[12,13] The number of healthy controls is twice the
number of MHS/ERM subjects as more variance is expected in
the healthy controls than in the MHS/ERM subjects.
3. Discussion
Although MH and ERM are considered to be episodic
manifestations ofRYR1 variants in otherwise healthy individuals,
there is increasing evidence for neuromuscular and multisystem
manifestation of disease in these patients. In the last decade,
knowledge of the full spectrum of RYR1-related myopathies has
significantly increased.[2] However, the full disease spectrum and
the effects of quality of life in affected patients are not fully
understood yet. This study aims to explore in detail the degree
and extent of neuromuscular and multisystem features of RYR1-
related MH and ERM. Results of this study will improve
recognition of multisystem symptoms in patients carrying
RYR1-variants and contribute to optimization of the diagnostic
work-up and counselling of patients with RYR1 variants. This
information will be of benefit to neurologists, anesthesiologists
and geneticists working in the field of MH, ERM and RYR1.
Furthermore, better understanding of the function of the RyR1 in
the immune system and the immunological features of function in
patients with RYR1 variants will give more insights into
immunological modifying factors relevant to the pathophysiology
of ERM and MH.
A major strength of this study is the random selection of the
study subjects from theMH and ERM cohort in two centers with
large expertise regarding research and clinical care for patients
with RYR1 variants. Previous studies on this topic focused on
special cases or a selected cohort which might have resulted in a
significant publication bias. We will include subjects from the
MH and ERM cohort including subjects who did not have a prior
neuromuscular assessment before inclusion. Therefore, wewill be
able to include a representative study population for the MH and
ERM cohort.
In conclusion, this study is expected to increase knowledge
of the full spectrum of neuromuscular and multisystem features
of RYR1-related MH and ERM and will establish a well-
characterized baseline cohort for future studies onRYR1-related
disorders. The results of this study are expected to improve
recognition of RYR1-related symptoms, counselling and a
more personalized approach to patients affected by these
conditions. Furthermore, results will create new insights in the
role of the immune system in the pathophysiology of MH
and ERM.
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